Exactech Settles Whistleblower Lawsuits for $8 Million Amid Allegations of Concealed Defects in Knee Implants
In a significant legal development, Exactech, a Florida-based medical device manufacturer, has agreed to pay $8 million to settle allegations that it concealed defects in its popular line of artificial knee implants. This settlement comes in the wake of multiple lawsuits claiming that the company’s knee replacement products have caused serious injuries to thousands of patients.
Background of the Allegations
The settlement resolves two whistleblower lawsuits filed under the federal False Claims Act, which accuses Exactech of knowingly billing government health care programs, including Medicare, for defective knee replacement parts. The U.S. Attorney for the District of Maryland, Kelly Hayes, emphasized the importance of patient safety, stating, “When a manufacturer learns that its device is defective, it must promptly and transparently address the problem.”
Exactech, which has been in operation for over three decades, declared bankruptcy in October 2022, leaving many injured patients in a precarious situation as they sought compensation. The U.S. Bankruptcy Court for the District of Delaware has approved the settlement, although Exactech has not admitted any liability in the matter.
The Impact on Patients
The ramifications of Exactech’s alleged negligence are profound. According to Florida attorney Joseph Saunders, who represents numerous patients in related lawsuits, over 2,500 individuals have filed claims for injuries linked to the company’s knee implants. Many of these patients have undergone multiple surgeries to remove and replace the defective implants, often within just a few years of their initial procedures. “There are people who are lifelong cripples from this or had multiple surgeries,” Saunders remarked, highlighting the severe consequences faced by many.
One affected patient, Sue Sacker from New Jersey, expressed her frustration with the settlement. After having two Exactech knee implants replaced, she stated, “I’m fuming. People are suffering, and the government is getting the money. Where are the patients? Who’s taking care of us?”
Whistleblower Cases and Legal Proceedings
The whistleblower lawsuits trace their origins back to 2018, when former Exactech sales agents Brooks Wallace and Robert Farley, along with former senior product manager Manuel Fuentes, filed the first case in federal court in Alabama. They alleged that Exactech was aware of serious defects in its Optetrak total knee replacement systems, which have been on the market since 1994. By 2008, the company reportedly knew that a component of the implant was failing at an unacceptable rate, yet it continued to market the product until December 2018.
In a separate whistleblower case, orthopedic surgeon Pasquale Petrera claimed that Exactech was aware of premature failures in certain Logic and Truliant brand knee replacement systems as early as January 2019. The company continued to sell these products until February 2022, when it expanded a recall. Under the terms of the settlement, the whistleblowers will receive a combined total of approximately $1.9 million.
Historical Context and Industry Implications
The Exactech case is not an isolated incident in the medical device industry. Over the years, numerous manufacturers have faced scrutiny for similar allegations of concealing defects in their products. The medical device sector has been under increasing pressure to prioritize patient safety and transparency, especially as technology advances and more complex devices enter the market.
A KFF Health News investigation published in October 2023 revealed that Exactech had reported approximately 400 adverse events to the government two years or more after becoming aware of them. Federal regulations require such reports to be submitted within 30 days unless a special exemption is granted. This delay raises serious questions about the company’s commitment to patient safety.
Moreover, an analysis of over 300 pending cases in Florida’s Alachua County found that surgeons had removed around 200 knee and hip implants after less than seven years-far shorter than the expected lifespan of 15 to 20 years for these devices. Exactech had previously marketed its implants as durable, even suggesting they would likely outlast their human recipients.
The Role of Private Equity
The settlement also raises questions about the role of private equity in the healthcare sector. TPG, a private equity firm, acquired Exactech for $737 million in February 2018. A committee of creditors is now considering pursuing TPG for its involvement, although the firm successfully argued last year that it did not exert control over Exactech’s operations. TPG has declined to comment on the ongoing situation.
Conclusion
The $8 million settlement by Exactech serves as a stark reminder of the critical importance of transparency and accountability in the medical device industry. As patients continue to suffer from the alleged defects in Exactech’s knee implants, the broader implications of this case may prompt regulatory changes and increased scrutiny of medical device manufacturers. The ongoing legal battles and the plight of affected patients underscore the need for a healthcare system that prioritizes patient safety above all else.
